Torcetrapib (formerly CP 529414; CP-529,414; CP-529414) is a novel and potent CETP (Cholesteryl ester transfer protein) inhibitor with the potential to lower cholesterol levels and to treat cardiovascular diseases.

Anacetrapib (formerly also known as MK0859; MK-0859), a poly-fluorinated lipophilic compound, is a selective and reversible inhibitor of CETP (Cholesteryl ester transfer protein) and mutant CETP(C13S) with the potential to treat cardiovascular disease.

Evacetrapib (also known as LY-2484595; LY2484595), a benzazepine compound, is a potent and selective inhibitor of CETP (Cholesteryl ester transfer protein) with the potential to lower cholesterol levels and to prevent cardiovascular diseases.

Dalcetrapib (formerly JTT-705; RO-4607381; JTT705; RO4607381) is a novel, potent and selective inhibitor of CETP (Cholesteryl ester transfer protein) with the potential to prevent cardiovascular diseases.